Effective immunotherapies for AD, PD, and ALS (including monoclonal antibodies and therapeutic vaccines for prion-like proteins such as beta-amyloid, tau, alpha-synuclein and TDP-43) are on the horizon. Here, SNCA is linked to Parkinson disease.